- Home
- FATE vs CRBP Comparison
FATE vs CRBP Comparison
Compare FATE & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- CRBP
- Stock Information
- Founded
- FATE 2007
- CRBP 2009
- Country
- FATE United States
- CRBP United States
- Employees
- FATE N/A
- CRBP N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- FATE Health Care
- CRBP Health Care
- Exchange
- FATE Nasdaq
- CRBP Nasdaq
- Market Cap
- FATE 116.5M
- CRBP 114.8M
- IPO Year
- FATE 2013
- CRBP N/A
- Fundamental
- Price
- FATE $0.96
- CRBP $9.37
- Analyst Decision
- FATE Hold
- CRBP Strong Buy
- Analyst Count
- FATE 6
- CRBP 10
- Target Price
- FATE $3.30
- CRBP $53.22
- AVG Volume (30 Days)
- FATE 1.4M
- CRBP 91.8K
- Earning Date
- FATE 11-11-2025
- CRBP 11-06-2025
- Dividend Yield
- FATE N/A
- CRBP N/A
- EPS Growth
- FATE N/A
- CRBP N/A
- EPS
- FATE N/A
- CRBP N/A
- Revenue
- FATE $8,470,000.00
- CRBP N/A
- Revenue This Year
- FATE N/A
- CRBP N/A
- Revenue Next Year
- FATE N/A
- CRBP $220.04
- P/E Ratio
- FATE N/A
- CRBP N/A
- Revenue Growth
- FATE N/A
- CRBP N/A
- 52 Week Low
- FATE $0.66
- CRBP $4.64
- 52 Week High
- FATE $4.20
- CRBP $56.93
- Technical
- Relative Strength Index (RSI)
- FATE 40.20
- CRBP 47.64
- Support Level
- FATE $0.93
- CRBP $9.42
- Resistance Level
- FATE $1.08
- CRBP $9.73
- Average True Range (ATR)
- FATE 0.06
- CRBP 0.49
- MACD
- FATE -0.01
- CRBP -0.09
- Stochastic Oscillator
- FATE 11.22
- CRBP 19.37
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.